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Colloidal drug carriers such as liposomes, lipid emulsions, and
polymeric nanoparticles have great potential to deliver drugs
effectively. Preparation of nano-crystals of API has also re-
ceived much attention to design dosage forms to complete
effective drug delivery. A variety of investigations have been
carried out toward the design of an optimal particulate system
in several administration routes for both systemic and topical
drug delivery. This presentation demonstrates recent ad-
vances in drug delivery using liposomal systems in several
administration routes, such as oral, pulmonary, and ocular
routes. Use of nano-crystals in delivering drug will be also
mentioned.
We succeeded previously in preparing mucoadhesive lipo-
somes by using chitosan as a coating polymer [1]. When
chitosan-coated liposomes containing a peptide drug such as
insulin or calcitonin were orally administered to rats, corre-
sponding pharmacological effects were observed. By decreasing
the diameter of liposomes coated with chitosan to submi-
cron size, the pharmacological effects were prolonged
extensively. When the intestinal tubes of rats were observed
by scanning confocal microscopy after administration of these
liposomes, liposome particles were found to have penetrated
the enteric mucus layer and then into the mucous layer deeply.
One of recent advances in polymer-coated liposomes for oral
administration of peptide drugs is modification of coating poly-
mers for increasing the delivery effect. For example, the
synergetic effect of carbopol and lectin in the oral adminis-
tration of calcitonin was confirmed by using carbopol–lectin
conjugate for coating the liposomes. Co-formulation of an ab-
sorption enhancer, spermine, into the liposomal formulation
has also led to improvement in the resultant pharmacologi-
cal effects of calcitonin formulated to the liposome. It is also
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a recent advance to use the in vivo imaging system (IVIS) for
detecting retention of the liposomal system in the intestinal
tract non-invasively after oral administration. More recently
we have succeeded in detecting the actual absorption of amodel
material, FITC-dextran, having higher molecular weight up to
10,000 by using the several types of polymer-coated lipo-
somes as carrier.
In characterizing the behavior of polymer-coated lipo-
somes in the lung, the similar effects of polymer-coated
liposomes were detected compared with non-coated lipo-
somes [2].We have also confirmed the effectiveness of polymer-
coated liposomes in the pulmonary administration of liposomal
calcitonin. The pharmacological effects after the administra-
tion of liposomal calcitonin reflected the behavior of the
liposomal particles characterized separately. IVIS was success-
fully used to confirm the good relation between the
pharmacological effect and retention of these liposomal par-
ticles in the lung as well as in oral administration.
The lack of noninvasive administration method to deliver
the drug to posterior segment of eyes is a problem to be solved
in treating posterior segment-related diseases such as age-
related macular degeneration (ARMD), diabetic macular edema
(DME), etc., which may cause serious symptoms such as vision
impairment and blindness. We have challenged to overcome
this issue by using liposomal systems [3]. To confirm the use-
fulness of liposomal systems for delivering drugs to the
posterior segments of the eye, we apply liposomal suspension
containing a fluorescent marker to the eye in mice.We could
detect the stronger fluorescence in the retina when submicron-
sized liposomes (ssLip) were used as a carrier in the eye drop
formulation.This finding strongly suggested that ssLip can ef-
fectively deliver the drug to the posterior part of the eye. Surface
modification effects have also been confirmed. Very recently,
we have demonstrated pharmacological effects of the lipo-
somal eye drops with some APIs and also succeeded in animal
scale up to detect the retina delivery with the liposomal
systems.
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